Adjudicatario

Novartis Gene Therapies EU Ltd.

Dublin 9 · IRL

Seguir este registroCon Adjudera Pro, reciba un aviso antes de que venza un contrato aquí.

Adjudicaciones

Importe total adjudicado

—

0 / 9 con importe

Órganos de contratación

Sectores

Reg. [Novartis Gene Therapies EU Ltd.]

Contratos de este adjudicatario próximos a vencer

31 dic 2026
declarada
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 22.0 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
declarada
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 27.5 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
declarada
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 30.3 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
declarada
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 33.0 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
declarada
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 35.8 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
declarada
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 38.5 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
declarada
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 52.3 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
declarada
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 55.0 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
declarada
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 60.5 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—

Todos los contratos próximos a vencer →

Adjudicaciones

Adjudicación	Órgano de contratación	Adjudicatario	Importe del contrato	Publicado
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 60.5 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 55.0 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 52.3 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 38.5 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 35.8 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 33.0 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 30.3 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 27.5 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 22.0 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026